

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CXCL3 RABBIT PAB

货号: S216529 产品全名: CXCL3 兔多抗 基因符号 GRO3; GROg; MIP2B; SCYB3; MIP-2b; CINC-2b UNIPROT ID: P19876 (Gene Accession - BC016308) 背景: Chemokine (C-X-C motif) ligand 3 (CXCL3) is a

背景: Chemokine (C-X-C motif) ligand 3 (CXCL3) is a small cytokine belonging to the CXC chemokine family that is also known as GRO3 oncogene (GRO3), GRO protein gamma (GROg) and macrophage inflammatory protein-2-beta (MIP2b). CXCL3 controls migration and adhesion of monocytes and mediates its effects on its target cell by interacting with a cell surface chemokine receptor called CXCR2. More recently, it has been shown that Cxcl3 regulates cell autonomously the migration of the precursors of cerebellar granule neurons toward the internal layers of cerebellum, during the morphogenesis of cerebellum.

抗原: Fusion protein of human CXCL3

经过测试的应用: ELISA, IHC 推荐稀释比: IHC: 15-50; ELISA: 1000-2000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human In ovarian cancer tissue using 216529(CXCL3 Antibody) at a dilution of Hu



In comparision with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with the fusion protein and then with 216529(Anti-CXCL3 Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffinembedded Human liver cancer tissue using 216529(Anti-CXCL3 Antibody) at a dilution of 1/25.



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D220677(Anti-CXCL3 Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010